New advances in DPYD genotype and risk of severe toxicity under capecitabine.

doi:10.1371/journal.pone.0175998

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

PloS one - 1 Jan 2017

Etienne-Grimaldi Marie-Christine, Boyer Jean-Christophe, Beroud Christophe, Mbatchi Litaty, van Kuilenburg André, Bobin-Dubigeon Christine, Thomas Fabienne, Chatelut Etienne, Merlin Jean-Louis, Pinguet Frédéric, Ferrand Christophe, Meijer Judith, Evrard Alexandre, Llorca Laurence, Romieu Gilles, Follana Philippe, Bachelot Thomas, Chaigneau Loic, Pivot Xavier, Dieras Véronique, Largillier Rémy, Mousseau Mireille, Goncalves Anthony, Roché Henri, Bonneterre Jacques, Servent Véronique, Dohollou Nadine, Château Yann, Chamorey Emmanuel, Desvignes Jean-Pierre, Salgado David, Ferrero Jean-Marc, Milano Gérard

Abstract excerpt

BACKGROUND: Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DPYD genotyping and phenotyping. The goal of this prospective observational study was to perform exhaustive exome DPYD sequencing and to examine relationships between DPYD variants and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antimetabolites, Antineoplastic

Share to Breast Neoplasms

Share to Capecitabine

Share to Dihydrouracil Dehydrogenase (NADP)

Share to DPYD gene

Share to Genotype

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 28481884
DOI: 10.1371/journal.pone.0175998
PMCID: PMC5421769

Genes

DPYD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New advances in DPYD genotype and risk of severe toxicity under capecitabine.PMID 28481884Read ↗

Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).Semantic proximity Read ↗

DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy.Semantic proximity Read ↗

Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants.Semantic proximity Read ↗

Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.Semantic proximity Read ↗

Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.Semantic proximity Read ↗

A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.Semantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.Semantic proximity Read ↗

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.Semantic proximity Read ↗

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.Semantic proximity Read ↗

Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population.Semantic proximity Read ↗

Opportunistic analysis of clinically actionable DPYD gene variants in a germline testing cohort in India.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.